Edgewise shares slip after heart-disease drug trial data disappoints investors

Edgewise Therapeutics shares fell nearly 10% after its experimental heart-disease drug delivered mid-stage efficacy results that fell short of investor expectations. The reaction suggests disappointment with the drug’s clinical profile and raises questions about the program’s commercial prospects. The move is likely to affect the stock individually rather than the broader sector.

Analysis

Edgewise Therapeutics shares fell nearly 10% after its experimental heart-disease drug delivered mid-stage efficacy results that fell short of investor expectations. The reaction suggests disappointment with the drug’s clinical profile and raises questions about the program’s commercial prospects. The move is likely to affect the stock individually rather than the broader sector.